Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Hydroxychloroquine might help prevent COVID-19, but more research is needed.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

Adapalene, Diosmin, and Azelastine could be repurposed to treat onchocerciasis.

Rituximab can cause skin issues, but baricitinib may help improve them.

Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.

Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.

Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.

Combining glycyrrhizin and UVB light is most effective for improving vitiligo.

Micelles can change cetirizine's ionization, affecting its effectiveness in treatments.

Talquetamab may cause hair loss and skin issues.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

The compound zishenqing formula is effective and safe for treating mild to moderate systemic lupus erythematosus.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

CGRP MAbs treatment for migraines may also improve rosacea symptoms, but more research is needed to confirm its effectiveness and safety.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.